Exploring the Real-World Effectiveness of Empagliflozin and Linagliptin Fixed-Dose Combination in Type 2 Diabetes Patients of Bangladesh: A Prospective Multi-Center Observational Study
Year: 2025
Type: article
Study design: Observational Study
Abstract: Purpose: The fixed-dose combination (FDC) of empagliflozin and linagliptin is a promising treatment for type 2 diabetes mellitus (T2DM), but real-world data from Bangladesh is limited. This study aimed to assess the effectiveness and safety of empagliflozin 10 mg/linagliptin 5 mg [Empa/Lina (10/5)] FDC among T2DM patients at real-world settings in Bangladesh. Patients and Methods: This prospective, multicenter, observational study enrolled 822 adults with T2DM across Bangladesh. Patients receiving Empa/Lina (10/5) FDC either alone or with other antidiabetic medications at practice were enrolled. Glycemic control, body mass index (BMI), blood pressure, and adverse events were assessed over three months. Results: Mean HbA1c decreased significantly from baseline to three months in both the Empa/Lina (10/5) FDC alone group (9.13% to 8.18%, p< 0.001) and the FDC plus other antidiabetics group (10.20% to 8.12%, p< 0.001). Fasting and post-prandial blood glucose levels also improved significantly (p< 0.001). BMI decreased from 26.81 kg/m 2 to 25.90 kg/m 2 (p=0.008). Systolic and diastolic blood pressure reduced by 11.09 mmHg and 4.41 mmHg, respectively (p< 0.001). The estimated glomerular filtration rate remained stable. Improvements were consistent across patient subgroups with various comorbidities. Adverse events were infrequent, with hypoglycemia (10.95%), genital mycotic infection (3.04%), and urinary tract infections (2.80%) being the most common. Conclusion: Empa/Lina (10/5) FDC demonstrated significant improvements in glycemic control, BMI, and blood pressure with a favorable safety profile in Bangladeshi patients with T2DM. These real-world findings support its use as an effective treatment option in this population. Keywords: type 2 diabetes mellitus, empagliflozin, linagliptin, fixed-dose combination, Bangladesh
DOI: 10.2147/dmso.s542107
Authors: Mirza Sharifuzzaman, Ajit Paul, Md Akteruzzaman, SN Haider Bhuiyan, Rezaul Haider, Shoma Sharker, Dahlia Sultana, Khondoker Alam, Sikandar Abu Zafar, Md Kashem, Md Abu Zahid, AFM Nazmul Islam, Md Zainal Abedin, Fouzia Anar, Md Farucul Hasan, Shahjada Selim, Sunjida Islam, Afsar Ahammed, Mobarak Hosen, Nazmul Qureshi, Mohammad Hossain, Aysha Begum, Farhana Afrooz, ASM Musa Kobir, Farhana Akter, Sadia Mustafa, Md Motiur Rahman, M Saifuddin
Institutions: Dhaka Medical College and Hospital, Sir Salimullah Medical College, Rangpur Medical College, Feni University, Sylhet MAG Osmani Medical College, North East Medical College, Bangladesh Medical University, Vavuniya General Hospital, Kumagaya General Hospital, Kamagaya General Hospital, Kashiwa Kousei General Hospital, Chittagong Medical College, Bangladesh Institute of Research and Rehabilitation for Diabetes Endocrine and Metabolic Disorders, Rajshahi Medical College
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,836
OpenAlex ID: W4416957225